ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FWP Forward Pharma AS

1.95
0.00 (0.00%)
06 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Forward Pharma AS NASDAQ:FWP NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 1.95 1.79 2.12 0 01:00:00

Report of Foreign Issuer (6-k)

24/10/2018 3:52pm

Edgar (US Regulatory)


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

October 24, 2018

Commission File Number: 001-36686

Forward Pharma A/S

Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes  [   ]  No  [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes  [   ]  No  [ X ]

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  [   ]  No  [ X ]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  N/A


Item 1. Issuance of Press Release

On October 24, 2018, Forward Pharma A/S issued a press release regarding the decision in the appeal to the U.S. Court of Appeals for the Federal Circuit of the decision of the U.S. Patent Trial and Appeal Board concerning its U.S. Patent Application No. 11/576,871, a copy of which is attached hereto as Exhibit 99.1.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   Forward Pharma A/S
     
     
   
Date: October 24, 2018  By: /s/ Claus Bo Svendsen    
     Name: Claus Bo Svendsen
     Title:   Chief Executive Officer
   

 


EXHIBIT INDEX

99.1   Press Release dated October 24, 2018
 

1 Year Forward Pharma AS Chart

1 Year Forward Pharma AS Chart

1 Month Forward Pharma AS Chart

1 Month Forward Pharma AS Chart

Your Recent History

Delayed Upgrade Clock